Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression
Abstract Lithium, a mood stabilizer and common adjunctive treatment for refractory depression, shares overlapping mechanisms of action with ketamine and enhances the duration of ketamine’s antidepressant actions in rodent models at sub-therapeutic doses. Yet, in a recent clinical trial, lithium co-t...
Guardado en:
Autores principales: | J. Blair Price, Clarissa G. Yates, Brooke A. Morath, Sam K. Van De Wakker, Nathanael J. Yates, Kim Butters, Mark A. Frye, Sean L. McGee, Susannah J. Tye |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/752ab944d2c949039ac5e787a45d034a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immunoregulation and antidepressant effect of ketamine
por: Zhang Nan, et al.
Publicado: (2021) -
The role of dissociation in ketamine’s antidepressant effects
por: Elizabeth D. Ballard, et al.
Publicado: (2020) -
Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
por: Naghmeh Nikkheslat
Publicado: (2021) -
BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study
por: Huang XB, et al.
Publicado: (2020) -
Augmentation with antidepressants in schizophrenia treatment: benefit or risk
por: Mao YM, et al.
Publicado: (2015)